Tasly invests $40mn in US centre as first traditional Chinese product enters Phase III
This article was originally published in Scrip
The major Chinese traditional Chinese medicine (TCM) manufacturer Tasly Pharmaceutical is investing about $40 million in a research, production and training facility in the US which it hopes will facilitate the commercial entry of its products into the country's prescription market.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.